Trial intelligence / Profile preview

Phase 3 double-blind placebo-controlled latrepirdine in moderate-to-severe Alzheimer's disease

2009-012456-25Phase 3Terminated

Sponsor: Pfizer
Start: Oct 2009
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Latrepirdine with Placebo (2 arms). Primary endpoints: Severe Impairment Battery (SIB) change from baseline at Week 26 (LOCF) and ADCS-ADLsev change from baseline at Week 26 (LOCF). Started Oct 2009; status: terminated.

Drugs

latrepirdine

Conditions

Alzheimer's disease (AD)

Beyond the preview

Go deeper on 2009-012456-25.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-012456-25.